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Abstract: Amyotrophic lateral sclerosis (ALS) is an incurable and fatal disorder characterized
by the progressive loss of motor neurons in the cerebral cortex, brain stem, and spinal cord.
Sporadic ALS form accounts for the majority of patients, but in 1–13.5% of cases the disease is
inherited. The diagnosis of ALS is mainly based on clinical assessment and electrophysiological
examinations with a history of symptom progression and is then made with a significant delay from
symptom onset. Thus, the identification of biomarkers specific for ALS could be of a fundamental
importance in the clinical practice. An ideal biomarker should display high specificity and sensitivity
for discriminating ALS from control subjects and from ALS-mimics and other neurological diseases,
and should then monitor disease progression within individual patients. microRNAs (miRNAs) are
considered promising biomarkers for neurodegenerative diseases, since they are remarkably stable
in human body fluids and can reflect physiological and pathological processes relevant for ALS.
Here, we review the state of the art of miRNA biomarker identification for ALS in cerebrospinal fluid
(CSF), blood and muscle tissue; we discuss advantages and disadvantages of different approaches,
and underline the limits but also the great potential of this research for future practical applications.
Keywords: amyotrophic lateral sclerosis (ALS); biomarker; microRNA; cerebrospinal fluid (CSF);
muscle biopsy; circulating miRNAs
1. Introduction
Amyotrophic lateral sclerosis (ALS), the most common adult-onset neurodegenerative disorder, is
an incurable and invariably fatal condition characterized by the progressive loss of motor neurons in the
motor cortex, brain stem, and spinal cord [1]. Motor neurons are selectively affected by degeneration
and death, however the collective evidence is that ALS is non-cell autonomous, but rather pathogenesis
and disease progression depend on the active participation of non-neuronal neighboring cells such
as microglia, astrocytes, muscle and T cells [2,3]. Motor neuron degeneration causes progressive
weakness of limb, thoracic, abdominal, and bulbar muscles.
During the early stages of the disease symptoms may vary depending on dysfunction of upper
motor neurons (UMN) in the motor cortex (resulting in hyperreflexia, extensor plantar response,
and increased muscle tone), or lower motor neuron (LMN) in the brainstem and spinal cord
(leading to generalized weakness, muscle atrophy, hyporeflexia, fasciculations, and muscle cramps) [1].
Patients with bulbar onset ALS usually develop slurred and nasal speech and difficulty chewing or
swallowing. Bulbar onset occurs less frequently than limb involvement, and accounts for about 25% of
ALS cases. During the disease course, most cases show the presence of both LMN and UMN signs
affecting spinal and brainstem regions [4]. Death, mainly due to bulbar dysfunction and respiratory
insufficiency, occurs within 2–4 years of first symptoms; however, a small group of patients with ALS
may survive for 10 or more years [5].
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1.1. Epidemiology and Genetic Factors
The incidence of ALS is 2.1 per 100,000 persons per year, with an estimated prevalence of 5.4
cases per 100,000 population [6]. Based on data collected by population-based registers, the incidence
of ALS increases after the age of 40, shows a peak in the late 60s or early 70s, and then displays a
fast decline [7]. The reported male to female ratio varies widely with the age: a sex ratio of 2 or
higher is observed for younger patients, while it appears to decrease towards 1 when the proportion
of older patients increases [8]. Over the years, several environmental and lifestyle risk factors have
been suggested as potential contributors to the cause of ALS. Nevertheless, no conclusive data are yet
available, and further studies are required to identify exogenous risk factors of ALS [7,9].
Most cases (around 90%) are classified as sporadic ALS (SALS), since they are not associated with
a documented family history. In 1–13% of patients the disease is inherited and defined as familial ALS
(FALS), most frequently with a Mendelian dominant inheritance and high penetrance, even though
pedigrees with recessive inheritance or incomplete penetrance have been described [10]. The mean age
of onset for FALS is 46 years and for SALS is 56 years. In familial ALS, age of onset displays a Gaussian
distribution, whereas an age-dependent incidence characterizes sporadic ALS [4]. Disease with an
onset prior to 25 years of age is defined as “juvenile ALS” [11]. Apart from the mean age of onset,
sporadic and familial forms are clinically indistinguishable suggesting a common pathogenesis.
Several genes have been associated with pathogenesis of ALS. The most common ALS causative
genes include chromosome 9 open reading frame 72 (C9orf72), Cu2+/Zn2+ superoxide dismutase
(SOD1), TAR DNA-binding protein 43 (TARDBP), and RNA binding protein FUS (FUS) [12–14], but a
lot of other genes have been associated with the disease [15]. Notably, the mutated genes in ALS
encode for proteins with very distinct functions in the cell. However, interestingly many ALS-linked
genes, particularly TARDBP and FUS, are involved in RNA metabolism, including microRNA (miRNA)
processing [16,17].
1.2. Diagnosis and Treatment
There is no objective laboratory test able to provide the diagnosis of ALS, which remains mainly
based on clinical assessment, electrophysiological examinations, and exclusion of conditions that can
mimic ALS. The certainty level of the diagnosis of ALS may be classified into different categories by
clinical and laboratory assessments based on El Escorial criteria [18].
Currently, riluzole and edaravone represent the only drugs approved by the FDA for ALS,
providing however a limited improvement in survival [5]. The most significant benefit of riluzole is
observed after intervention in the early stages of the disease [19]. Thus, an early diagnosis of ALS
could provide the most effective results. Since diagnosis of ALS relies on clinical symptoms, and the
time from the first symptoms to diagnosis is about 12 months, there is a delay hindering a successful
therapy [5]. This phenomenon underlies the importance of the development of screening tests able to
detect the disease in early stages.
2. Role of Biomarkers in ALS
In the last years, research has been focused on the identification of potential biological markers to
use in diagnostic procedure and clinical practice.
According to the National Institutes of Health Biomarkers Definitions Working Group,
a biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention” [20]. Biomarkers can be classified into three general categories: (1) diagnostic biomarkers,
which are used for differential diagnosis; (2) prognostic biomarkers, which can differentiate a good or
a bad outcome of the disease; and (3) predictive biomarkers, which are utilized for assessing whether a
treatment may be effective for a specific patient or not.
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In the case of ALS, biomarkers would allow an earlier and more accurate diagnosis, with the
opportunity to start an earlier treatment able to modify the disease course. They could help the
classification/stratification of ALS patients, monitor the disease progression and identify patients
who will respond better to a particular drug. Biomarkers can also provide a valuable tool for
the identification of new therapeutic approaches and drive patients’ enrollment in clinical trials.
Furthermore, they may represent a link between the results obtained in animal models and the human
patients, providing insight on potential therapeutic targets.
Over the last two decades, intensive work has been carried out to find consistent biomarkers for
ALS. Several candidates involved in excitotoxicity, oxidative stress, neuroinflammation, metabolic
dysfunction, and neurodegeneration processes have been explored [21], but, unfortunately, none of
these biomarkers has been currently translated into a practical diagnostic tool.
3. miRNAs as Biomarkers
Recently, among the different categories of potential biomarkers, miRNAs have aroused great
interest in several fields of research. miRNAs are short (about 22 nucleotides in length) non-coding
RNA molecules that play an important role as endogenous regulators of gene expression acting at
the post-transcriptional level. miRNAs are synthesized from primary miRNAs, which are transcribed
in the nucleus. Primary miRNAs are processed into pre-miRNAs by Drosha and then exported to
the cytoplasm. Pre-miRNAs are eventually processed by the Dicer complex, resulting in mature
miRNAs, which form RNA-induced silencing complexes [22]. miRNAs have a tissue-specific
expression and this knowledge can help to better understand a normal and a disease development
of the respective tissue [23]. miRNAs are known to play important roles in many physiological
and pathological processes, including tumorigenesis [24], metabolism [25], immune function [26],
and several neurodegenerative disorders [27], such as Parkinson’s disease, Alzheimer’s disease,
Huntington’s disease [28] and also ALS [29].
miRNAs have several intrinsic characteristics that make them promising as biomarkers. An ideal
biomarker should display high sensitivity, specificity, and predictive power. miRNAs have been shown
to have high specificity, and, in particular in cancer research, where a plethora of publications has
been generated, it has been demonstrated that miRNA expression profiles differ among cancer types
according to diagnosis and developmental stage of the tumor, with a better resolution than traditional
gene expression analysis [30]. Moreover, unlike other RNA classes, miRNAs are remarkably stable and
therefore can be robustly measured in many biological body fluids including plasma, tears, saliva and
cerebrospinal fluid [31]. Indeed, miRNAs appear resistant to boiling, repeated freeze-thawing cycles,
pH changes, and fragmentation by chemical or enzymes [32–34]. Furthermore, recent evidence
indicates that miRNAs can be detected in biological fluids and can be used to “capture” changes in the
cells of origin, including neurons [35].
In addition to these general considerations, several findings suggest a specific involvement of
miRNAs in ALS. For example, the loss of Dicer is sufficient to cause progressive degeneration of
spinal motor neurons [36]; in addition, a global down-regulation of miRNAs is a frequent molecular
denominator for multiple forms of human ALS [37]. Moreover, a common theme for several
ALS-related genes is a role in RNA processing pathways [38]. FUS facilitates co-transcriptional
Drosha recruitment to specific miRNA loci [39] and TARDBP participate to miRNA biogenesis as a
component of both Drosha and Dicer complexes [16].
miRNA Detection
During the last decade, the development of methods for detecting miRNAs has risen to become a
very attractive area of research. Although miRNAs have characteristics that made them suitable
biomarkers, the detection of these molecules is challenging due to their intrinsic characteristics
including small size, sequence similarity among various members, low level and tissue-specific or
developmental stage-specific expression. Two approaches commonly used in the research of miRNAs
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as biomarkers, including studies in the area of neurodegenerative diseases and in particular in ALS,
are reported below.
(1) Measurement of hundreds of miRNAs in specimens from patients with a pathology of
interest and from control subjects using profiling methods, such as microarray, quantitative Real-Time
Polymerase Chain Reaction (qRT-PCR)-based array, quantitative nCounter or Next Generation
Sequencing (NGS), with subsequent validation of identified miRNAs by qRT-PCR;
(2) Analysis of selected miRNA(s) already known as related to specific tissues, cell types, or gene
expression pathways. In this case, the number of miRNA(s) to be tested is limited, which makes the
use of individual qRT-PCR appropriate, increasing sensitivity and reproducibility of the analysis.
Among the profiling methods, microarray is a powerful high-throughput widely used tool that
screens large numbers of miRNAs analyzing simultaneously several samples processed in parallel in a
single experiment [40]. An alternative method is deep-sequencing, which relays on NGS machines
that can process millions of sequence reads in parallel in just a few days [41,42]. Sequence reads are
processed by bioinformatics analysis, which identifies both known and novel miRNAs in the data
sets, and perform a relative quantification using a digital approach [43]. Finally, qRT-PCR arrays
can also be used to detect multiple miRNAs at the same time [44]. This approach is able to detect
miRNAs in very low copy number [45]. This is an important aspect, since large amounts of RNA from
clinical samples can be difficult to obtain. Other advantages of qRT-PCR-based techniques used in
routine diagnostic are sensitivity, specificity, speed and simplicity [46]. Of note, potential biomarkers
selected by array-based analysis need to be confirmed by qRT-PCR, due to high variability and low
reproducibility of results obtained from these techniques [47].
A critical issue in qRT-PCR analysis is the data normalization approach. Normalization refers to
adjusting for variations in data that are due to known factors (usually technical factors) and not related
to the biological differences that are being investigated, and that could otherwise lead to inaccurate
quantification. For this reason, stable normalizers are needed, but identifying such molecules is
challenging, and it is often necessary to select them on a case-by-case basis [48]. Normalization
to reference invariant miRNAs [49] is effective in many cases, but this approach requires that the
reference miRNA is not influenced by the condition being studied. Exogenous spike-in controls
added to samples during the miRNAs extraction may be used to compensate the variability caused
by extraction efficiency and possible presence of inhibitors [50]. The combined use of two or more
normalizers usually allows reducing experimental variability and improving reliability of the analysis.
4. miRNAs as Biomarkers for ALS
The first paper about miRNAs as biomarkers for ALS in human samples was published by De
Felice and colleagues in 2012 [51]. Since then, a large number of studies have been performed on
cerebrospinal fluid (CSF), blood and muscle biopsies from ALS patients. See Figure 1 for a schematic
workflow of identification of miRNA-based biomarkers.
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Figure 1. icro ( i )-based bio arkers in a yotrophic lateral sclerosis (ALS) patients.
Sche atic orkflo to identify possible i s as bio arkers starting from ALS patients’ sample
using different quantitative approaches. The comparison among the common characteristics of miRNA
detection platforms is summarized in the figure. Sensibility, specificity and throughput are classified as
follows: +++ (very high), ++ (moderate), +/++ (moderate to low) and + (low). Abbrevations: qRT-PCR,
quantitative Real-Time Polymerase Chain Reaction; NGS, Next Generation Sequencing.
4.1. miRNAs in Cerebrospinal Fluid
Cerebrospinal fluid (CSF) is the fluid that bathes the central nervous system (CNS) and, due to this
direct interaction, represents a potentially ideal source for identifying biomarkers for ALS. miRNAs
present in CSF can mirror CNS physiological and pathological conditions representing more sensitive
biomarkers of brain changes than those present in other biofluids [35]. The presence of miRNAs in
CSF was first demonstrated by Cogswell and colleagues [52]. The authors reported that the amount of
miRNAs secreted or excreted from other organs to CSF is very limited and that the major source of
miRNAs detected in CSF are immune cells present in this biofluid. In addition, other studies showed
that the miRNAs present in CSF derived also from neurons [53].
CSF samples are obtained by lumbar puncture, a procedure used for diagnostic purposes
to confirm ALS diagnosis and exclude other pathologies, as inflammatory nerve conditions.
Lumbar puncture, however, represents an invasive procedure, that cannot be repeated during the
disease course for ethical implications. Thus, analysis of miRNAs in CSF is not suitable to identify
biomarkers to follow disease progression.
Up to date, five studies have been published about the identification of miRNAs as biomarkers in
CSF from ALS patients. Results are shown in Table 1.
The first three studies in Table 1 selected a limited set of miRNAs to analyze: 43 miRNAs found
up-regulated in SOD1 spinal cord CD39+ microglia and splenic Ly6Chi monocytes [54], a group of
TARDBP binding miRNAs [55], or one selected miRNA, over-expressed in ALS blood leucocytes [56],
respectively. The other two studies performed a miRNA expression profiling, using qRT-PCR [57] or
s all RNA sequencing (NGS) [58]. In both profiling studies, results were validated by qRT-PCR for
each single miRNA. While Benigni and colleagues found eight out of fourteen miRNAs as significantly
deregulated, Waller and coworkers failed to confirm statistically significant differences in miRNA
expression [57,58].
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Table 1. Deregulated microRNAs (miRNAs) in cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis
(ALS) patients compared to healthy controls.
miRNA (Hsa-miR) miRNA ExpressionChange No. of Specimens
miRNA Detection
Approach Ref.
150, 99b,
146a
27b, 328,
532-3p
↑ in SALS
↑ in SALS and FALS
SALS: 10
FALS: 5
HCs: 10
qRT-PCR [54]
132-5p, 132-3p,
143-3p
143-5p, 574-5p
↓
↑
SALS: 22
HCs: 24 qRT-PCR [55]
338-3p ↑ SALS: 10HCs: 10 qRT-PCR [56]
181a-5p
21-5p, 195-5p,
148-3p, 15b-5p,
let7a-5p, let7b-5p,
let7f-5p
↑
↓
SALS: 24
HCs: 24 qRT-PCR [57]
124-3p, 127-3p,
143-3p, 125b-2-3p,
9-5p, 27b-3p
486-5p, let7f-5p,
16-5p, 28-3p,
146a-3p, 150-5p,
378a-3p, 142-5p,
92a-5p
↑
↓
SALS: 32
HCs: 10
NCs: 6
NGS [58]
Abbreviations: Ref., Reference; ↑/↓, up-regulated/down-regulated; SALS, sporadic amyotrophic lateral sclerosis
patients; FALS, familial amyotrophic lateral sclerosis patients; HCs, healthy controls; NCs, neurological
disease control subjects (multiple sclerosis); qRT-PCR, quantitative Real-Time Polymerase Chain Reaction; NGS,
Next Generation Sequencing.
A common feature observed by the authors is an overall down-regulation of miRNAs in CSF
samples from ALS patients [55,57,58], in agreement with other studies showing that the majority of
deregulated miRNAs in tissues from ALS models and ALS patients are down-regulated [59]. This could
suggest a general default in RNA metabolism in ALS [38].
In general, however, these studies highlight a wide heterogeneity among miRNAs significantly
deregulated. A possible explanation could be the variability in terms of experimental approach and
technical procedures and the reduced number of CSF samples analyzed in each study.
Some authors evaluated the correlation between CSF and serum miRNA expression levels.
A significant positive correlation between expression levels in CSF and serum from ALS patients
was found for miR-338-3p [56] and miR-143-3p [55]. However, the amount of most miRNAs was
independently regulated between the two biofluids at individual level. This suggests that CSF miRNAs
do not simply reflect the usually more abundant serum miRNAs, and changes in the serum do not
necessarily reproduce alterations of CSF levels [55].
It should be noted that, among the different body fluids, the lowest abundance of miRNAs appears
in CSF. Thus, it is possible that some potentially promising and informative miRNAs, identified both
in vivo and in vitro ALS models, are below the limit of detection of the available methods of analysis.
For example, the miR-218, a motor neurons-enriched miRNA, has been found increased in CSF of
ALS rodent models: its expression correlates with the number of remaining spinal motor neurons
and is responsive to motor neuron sparing therapy [60]. miR-218 could thus represent a potential
biomarker to assess drug effects on motor neurons during clinical trials in ALS patients. However,
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at the present time, this miRNA is detectable only in some CSF samples, and thus a comparison
between ALS patients and controls is not possible.
An approach to overcome the technical limits due to low abundance of several miRNAs in CSF
could be to focus on those miRNAs found up-regulated in ALS patients. Among these, miR-338-3p
seems to be very promising, since it has been reported as consistently upregulated in CSF, serum and
leukocytes from ALS patients [56]. miR-338-3p is involved in several molecular pathways and could
contribute to ALS pathogenesis through different modalities, such as neurodegeneration and apoptosis.
Recent evidence suggests that miR-338 participates in the control of neuroblast apoptosis and in
neuroblastoma pathogenesis [61] and it is able to suppress neuroblastoma proliferation, invasion and
migration [62]. Interestingly, also another miRNA found up-regulated in CSF from ALS patients,
miR181a-5p, has been proposed as an anti-oncomir, which acts as a tumor suppressor in normal tissues,
promoting growth inhibition and apoptosis [63]. These findings suggest that these up-regulated
miRNAs are involved in ALS pathogenetic process through apoptotic mechanisms responsible for
cell death.
In order to increase diagnostic accuracy, up-regulated miRNAs can be used in combination with
other miRNAs, identified as down-regulated. Benigni and colleagues reported that the ratios of
miR-181a-5p/miR-15b-5p and miR-181a-5p/miR-21-5p considerably increased the specificity with a
slight decrease in sensitivity compared with each individual miRNA [57]. A wider use of this strategy
could allow improvements in the performance of identified biomarkers and should be taken into
account for future studies, as further discussed in the following paragraphs.
4.2. Circulating miRNAs
The use of blood samples in the diagnostic routine presents several advantages. Blood specimens
are easy to obtain, process and store, and the samples required for the analysis can be collected
without using invasive procedures for the patients. The lack of ethical implications as compared with
CSF and muscle biopsy makes it possible to repeat the blood draw during the disease progression.
Since miRNAs circulate in the blood in a highly stable form, this may facilitate the procedure of storage
and conservation and increase the flexibility of the analysis.
Blood-based biomarkers may originate from the CNS through a transfer between the blood and
CSF at the blood–CSF barrier [64,65], suggesting that the same biomarkers could be present in both
biofluids. They may be generated also by other organs and tissues affected during ALS, such as
degenerating muscles or peripheral blood cells. Therefore, blood can represent an excellent biofluid
for discovery and validation of biomarkers for ALS [66]. On the other hand, miRNAs present in
blood can reflect other pathophysiological conditions concurrent but not directly related to ALS
disease (e.g. inflammatory status, response to pharmacological treatments, etc.), which may represent
confounding factors.
Several studies on circulating miRNAs as potential biomarkers for ALS have been published.
The findings from such studies are summarized in Table 2.
Table 2. Deregulated circulating microRNAs (miRNAs) in amyotrophic lateral sclerosis (ALS) patients
compared to healthy controls.
miRNA (Has-miR) Expression
Change Source miRNA Detection Approach
No. of Specimens
for miRNAs
Validation
Ref.
↑: 338-3p Leukocytes Microarray→miRNAs validationwith qRT-PCR
SALS: 14
HCs: 14 [51]
↑: 27a, 155, 142-5p, 223, 30b,
532-3p
Monocytes
(CD14+ CD16-)
Nanostring nCounter 1 →
miRNAs validation with qRT-PCR
SALS: 22
FALS: 4
HCs: 24
[54]
↓: 132-3p, 132-5p, 143-3p, 143-5p,
let-7b Serum
Nine TARDBP binding miRNAs
and miR-9-5p→ qRT-PCR
SALS: 22
HCs: 24 [55]
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Table 2. Cont.
miRNA (Has-miR) Expression
Change Source miRNA Detection Approach
No. of Specimens
for miRNAs
Validation
Ref.
↑: 206, 106b Serum Microarray
1 →miRNAs
validation with qRT-PCR
SALS: 12
HCs: 12 [67]
↑: 338-3p Leukocytesand serum miR-338-3p→ qRT-PCR
SALS: 10
HCs: 10 [56]
↓ in FALS/SALS: 4745-5p, 3665,
4530
↓ in FALS: 1915-3p
Serum Microarray→ miRNAs validationwith qRT-PCR
FALS: 23
HCs: 24
SALS: 14
HCs: 14
[68]
↓ in FALS/SALS: 1825
↓ in SALS: 1234-3p Serum
Microarray→miRNAs validation
with qRT-PCR
SALS: 20
HCs: 20
FALS: 13
HCs: 13
[69]
↑: 4649-5p
↓: 4299 Plasma
Microarray→ miRNAs validation
with qRT-PCR
SALS: 48
HCs: 47 [70]
↓: 183, 193b, 451, 3935 Leukocytes Microarray→ miRNAs validationwith qRT-PCR
SALS: 83
HCs: 61 [71]
↑: 424, 206 Plasma Microarray
2 →miRNAs
validation with qRT-PCR
SALS: 39
HCs: 39 [72]
↑: 206, 133a,133b
↓: 146a, 149*, 27a Serum
Preselected myo-miRNAs,
inflammatory and angiogenic
miRNA→ qRT-PCR
SALS: 14
HCs: 8 [73]
↑: 206
Deregulated MicroRN
pairs: 206/338-3p
9*/129-3p
335-5p/338-3p
Plasma
Thirty seven brain-enriched and
inflammation-associated
microRNAs→ qRT-PCR
ALS: 50
HCs: 50 [74]
↑ †: 1, 133a-3p, 133b, 144-5p,
192-3p, 195-5p, 19a-3p
↓ †: let-7d-3p, 320a,
320b, 320c, 425-5p, 139-5p
Serum qRT-PCR array
SALS: 20
FALS: 3
HCs: 30
NCs: 103
[75]
↑: 206, 143-3p
↓: 374b-5p Serum
qRT-PCR array→miRNAs
validation with qRT-PCR
SALS: 23
CRL: 22 [76]
↑: 9, 338, 638, 663a, 124a, 451a, 132,
206, let-7b Leukocytes
Preselected 10 miRNAs→
miRNAs validation with qRT-PCR
SALS: 84
HCs: 27 [77]
↑: 142-3p
↓: 1249-3p Serum
Microarray 1 →miRNAs
validation with qRT-PCR
SALS: 20
HCs: 20 [78]
↓: 27a-3p Serumexosomes miR-27a-3p→ qRT-PCR
ALS: 10
HCs: 20 [79]
↓: let-7a-5p, let-7d-5p, let-7f-5p,
let-7g-5p, let-7i-5p, 103a-3p,
106b-3p, 128-3p, 130a-3p, 130b-3p,
144-5p, 148a-3p, 148b-3p, 15a-5p,
15b-5p, 151a-5p, 151b, 16-5p,
182-5p, 183-5p, 186-5p, 22-3p,
221-3p, 223-3p, 23a-3p, 26a-5p,
26b-5p, 27b-3p, 28-3p, 30b-5p,
30c-5p, 342-3p, 425-5p, 451a,
532-5p, 550a-3p, 584-5p, 93-5p
Whole blood NGS→ qRT-PCR SALS: 50HCs: 15 [80]
1 analysis carried out on samples from transgenic mice; 2 analysis carried out on samples of ALS patients’
skeletal muscle biopsies; †, miRNAs deregulated in ALS patients compared to healthy controls and neurological
controls (including multiple sclerosis and Alzheimer’s disease patients). Abbreviations: Ref., Reference; ↑/↓,
up-regulated/down-regulated; SALS, sporadic amyotrophic lateral sclerosis patients; FALS, familial amyotrophic
lateral sclerosis patients; HCs, healthy controls; NCs, neurological controls; qRT-PCR, quantitative Real-Time
Polymerase Chain Reaction; NGS, Next Generation Sequencing.
As reported in Table 2, several studies have identified numerous potential miRNA biomarkers in
peripheral blood from ALS patients, however their results rarely overlap with each other. This high
discrepancy in the identified miRNAs is probably associated with the variability of quantification
methods, miRNA normalizers used, number of samples included, clinical features of patients, and also
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with the differences in selected source of miRNAs (serum, plasma, leukocytes, and whole blood).
Another possible reason for the poor reproducibility of results may be the high level of heterogeneity
in miRNA profiles of SALS patients in comparison to FALS patients. Freischmidt and colleagues
initially reported a signature of 22 miRNAs significantly down-regulated in FALS and presymptomatic
mutation carriers [68]. Subsequently, the same authors replicated the analysis of these miRNAs in a
larger SALS sample group using identical technical procedures, and found only 2 miRNAs significantly
down-regulated in all SALS patients. A more accurate analysis of results revealed that around 60%
of SALS patients shared a serum miRNA fingerprint with genetic cases, while the remaining around
40% of patients were evenly distributed among control samples. The absence of FALS-like miRNA
patterns in these patients may mirror a higher impact of exogenous factors and possibly a lower and/or
different genetic influence in a subgroup of SALS patients [69].
Interestingly, the miRNA expression profiles derived from the study performed by Freischmidt
and colleagues [68] were re-elaborated applying principal component analysis (PCA)-based
unsupervised feature extraction (FE), another analysis approach [81]. The authors identified a total
of 51 deregulated miRNAs, 27 down-regulated and 24 up-regulated in ALS patients in comparison
with healthy controls. Applying the linear discriminant analysis (LDA) to these selected miRNAs,
overall accuracy was 0.66 including healthy controls, ALS mutation carriers, FALS and SALS patients.
Of note, excluding SALS patients, LDA was able to successfully discriminate healthy controls,
ALS mutation carriers and FALS patients, with an accuracy rising up to 0.84, confirming as the
heterogeneity of SALS group can introduce a wider variability in circulating miRNA profiles.
Among the studies published until now, a largely used approach is miRNA profiling on blood
samples from ALS patients and controls, carried out by microarray [51,68–71], PCR-array [75,76]
and NGS [80]. Other studies performed analysis on specific miRNAs, selected from data previously
reported in the literature [55,56,73,74,77]. In other cases, the first step of the research was a microarray
analysis on samples from transgenic mice [54,67,78] or skeletal muscle biopsies from ALS patients [68],
followed by validation of miRNAs found deregulated in the first step of analysis.
Only one study analyzed miRNA expression specifically in serum exosomes [79]. Exosomes are
double lipid vesicles secreted by a variety of cells and widespread in the peripheral body fluid.
They can reflect physiological and pathological changes of the cells of origin, representing potential
new biomarkers for disease diagnosis [82]. miRNAs are enriched in exosomes, and the exosome
membrane structure can protect them from degradation by RNA enzymes. The authors investigated
the expression of only miR-27a-3p, previously reported as present in myoblast-derived exosomes [83],
and found a down-regulation of this miRNA in ALS patients, suggesting that miRNA exosome analysis
could represent a future perspective for ALS biomarker identification.
Despite a poor overlapping among the miRNAs identified as deregulated in ALS, some circulating
miRNAs seem to be particularly promising as potential biomarkers in ALS patients. Table 3 summarizes
these miRNAs, reported as de-regulated in two or more papers.
As shown in the Table 3, some common pathways emerge: some miRNAs are involved in
neurodegeneration and apoptosis (miR-338, miR-142, miR-183 and let-7d), other miRNAs act at
muscle level (miR-206, miR-133a, miR-133b and miR-27a). In particular, miR-206, miR-133a and
miR-133b are myo-miRNAs, molecules specifically expressed in striated muscle and involved in
muscle proliferation, repair and regeneration. Their expression levels change during the process
of myogenesis, development, atrophy, degeneration, and myopathies [84]. The more recurrent
result is an up-regulation of circulating miR-206 in ALS patients. miR-206 is a human skeletal
muscle-specific miRNA that promotes the formation of new neuromuscular junctions following
nerve injury, and therefore plays a crucial role in the reinnervation process [85]. In miR-206 knock-out
mice, delayed and incomplete muscular reinnervation was observed in comparison to those animals
that expressed miR-206. In addition, high expression levels of miR-206 were found in a mouse model of
ALS, and its under-expression was associated with a faster progression of the disease [86]. A consensus
for higher expression levels of this miRNA in ALS patients compared to controls was reported by
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several authors [67,72–74,76,77]. Although miR-206 seems to represent a valid circulating biomarker
for ALS, it is still to define whether the elevated expression of this miRNA is the result of the disease
or its cause.
Table 3. The most promising circulating microRNAs (miRNAs) detected as potential biomarkers in
amyotrophic lateral sclerosis (ALS) patients.
miRNAs
(Has-miR)
miRNA
Change Role in ALS Ref.
206 ↑ Myo-miRNA: muscle proliferation, repair and regeneration. Itpromotes neuromuscular connectivity and enhances reinnervation [67,72–74,76,77]
338 ↑ Involvement in different pathways such as apoptosis,neurodegeneration, and/or glutamate clearance [51,67,74,77]
133a ↑ Myo-miRNA: muscle proliferation, repair and regeneration [73,75]
133b ↑ Myo-miRNA: muscle proliferation, repair and regeneration [73,75]
142 ↑ miRNA predicted to target a specific set of genes associated to thepathophysiology of ALS, including TARDBP and C9orf72. [54,78]
183 ↓
miRNA involved in neurodegenerative signaling pathway,
including PI3K-Akt and MAPK pathway. miR-183/mTOR
pathway contributes to spinal muscular atrophy pathology
[71,80]
27a ↓ miRNA involved in muscle growth, myoblast proliferation actingon myostatin. It is present in myoblast-derived exosomes [73,79]
let-7d ↓ Involvement in apoptosis by the Hippo signaling pathway [75,80]
Abbreviations: Ref., Reference; ↑/↓, up-regulated/down-regulated.
While all the works performed a comparison between samples from ALS patients and healthy
controls, only a subset of them included also samples from patients affected by other neurological
disorders. Neurological controls comprised Parkinson’s disease [56,70,71,74], Alzeihmer’s Disease [56,
69,74,75], Huntington’s disease [56,69,71], Multiple Sclerosis [54,75] and ALS-mimic conditions [76].
The use of neurological controls can help to discriminate whether identified miRNAs are really specific
for ALS or are common features linked to neurodegenerative processes. For example, the comparison
of miRNA expression between ALS and Parkinson’s disease patients suggested that miR-183 might
be specific for SALS, whereas miR-451 and miR-3935 might be more general biomarkers linked to
neurodegenerative disorders [71]. In addition, the inclusion of an ALS-mimic patients’ group may
contribute to identify miRNA biomarkers to use in the differential diagnosis in the early stages of
the disease.
Only a part of the studies performed until now investigated the potential correlations among
miRNA expression levels and ALS clinical features, sometimes in longitudinal studies, measuring
miRNA levels in the same ALS patient over time [70,72,75,76,80]. In some case this analysis failed
to find any association [67,69,77], in other cases specific correlations were reported. Some authors
described associations of miRNA expression levels with ALS site of onset [70,74,76,80], ALS Functional
Rating Scale-revised (ALSFRS-R) and/or vital capacity (VC) [70,75,78,80], Medical Research Council
(MRC) sumscore [72] and with the disease progression rate [72,80]. Only two studies investigated
the possible associations of specific serum miRNAs with riluzole treatment, failing to identify any
correlation [75,76]. Such results must be anyway considered with caution, since the number of
subjects included in every group is limited. They need to be confirmed in larger cohorts of ALS
patients, to really define the role of miRNA expression in ALS clinical presentation and progression.
From this perspective, it would be very important that, after the identification of potential miRNA
biomarkers, more longitudinal studies were performed, to evaluate if these miRNAs could be used as
prognostic indicators.
As already mentioned for CSF studies, also in serum the analysis of combinations of several
miRNAs has shown a higher accuracy than single miRNAs in discriminating ALS from healthy controls
or other neurological disorders [71,74,75]. A very interesting approach is reported by Sheinerman and
colleagues, who developed a strategy based on miRNA pairs, consisting of one miRNA enriched in
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synapses of a brain region affected by the disease and another miRNA enriched in a different brain
region or cell type. The use of the pair of miRNA derived from the same organ allowed decreasing
potential overlap with pathologies of other organs and reducing also inter-individual variability.
The authors demonstrated that, combining two or three effective miRNA pairs into a single miRNA
classifier, they could achieve a greater accuracy in discriminating ALS both from healthy controls
and patients affected by other neurological disorders [74]. Thus, in the future studies it should
be considered that, while the deregulation of a single miRNA can be a feature common to several
neurological diseases, panels of deregulated miRNAs, or combinations of them, may result highly
specific for ALS and represent a signature for this disease.
Finally, a relevant aspect of the use of miRNAs as ALS biomarkers is their potential of identifying
the disease in very early stages, also before any clinical manifestation. In their work, Freischmidt and
colleagues showed that a specific subset of miRNAs, reduced in the serum of patients with familial and
sporadic ALS, was reduced also in presymptomatic carriers of pathogenic ALS mutations. Moreover,
the down-regulation was largely independent of the underlying disease gene and was stronger in
patients with familial ALS than in pre-manifest mutation carriers, suggesting that alterations of miRNA
profiles could be progressive when comparing the pre-manifest and manifest phase of the disease [68].
If confirmed, these findings may be of fundamental importance for the development of screening tests
able to detect ALS in early asymptomatic stages and for future preventive therapeutic strategies before
the occurrence of clinically evaluable symptoms.
4.3. miRNAs in Muscle Biopsies
Skeletal muscle is another potential source for the identification of candidate miRNA biomarkers.
In the last years, it has become evident that ALS does not affect only motor neurons but also other
cell types, including striated muscle, which play an active role in the disease pathogenesis. Before the
clinical onset and during the disease progression, the affected skeletal muscle of ALS patients attempts
to restore function by futile cycles of reinnervation and denervation [87]. Eventually, persistent muscle
wasting exceeds the ability to repair and consequently the atrophy process starts. Due to the crucial
role of the skeletal muscle in ALS pathogenesis, recent studies have focused their research on the
identification of specific muscle miRNAs in ALS tissues, which could potentially be use as prognostic
biomarkers of disease. Moreover, miRNAs identified in skeletal muscle of ALS patients could be used
as biomarkers also in plasma or serum, where they can be released by the affected tissues. This strategy
seems to be particularly interesting, since muscle biopsy is unfortunately an invasive practice and
cannot be proposed for longitudinal studies to follow disease progression.
Several studies focused on analysis of myo-miRNAs, including miR-1, miR-133a, miR-133b,
miR-206, miR-208a, miR-208b, miR-499, and miR-486 [88]. Most of them explored the role of these
miRNAs in mouse models (for a review see [89]), but only few studies investigated the role of these
molecules as possible markers in muscle biopsies of patients with ALS, due to the rarity and difficulty
to obtain this kind of samples. miRNAs found deregulated in muscle biopsies from ALS patients
compared to healthy control subjects are shown in Table 4.
Most studies focused on the expression of myo-miRNAs [90–93]; only in some cases also other
miRNAs were included, for example miRNAs related to inflammation/angiogenesis [93] or selected
by microarray [72] or NGS approaches [94,95]. Overall, results are sometimes contrasting and poorly
reproducible. These non-concordant finding could be attributed to different types of muscle used
for biopsy, discordance among the samples in terms of inclusion criteria of patients (age, gender,
evolution of disease, onset) and different techniques and internal control molecules used to assess
miRNA expression levels.
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Table 4. Deregulated miRNAs in skeletal muscle biopsies of amyotrophic lateral sclerosis (ALS) patients
compared to healthy controls.
miRNA
(Hsa-miR)
miRNA
Expression
Change
Type of
Muscle
No. of
Muscle
Biopsies
miRNA Detection Approach Ref.
206 ↑ Deltoid,anconeus
FALS: 1
SALS: 10
HCs: 6
mir-206→ qRT-PCR [90]
23a, 29b, 206,
455, 31 ↑ Vastus lateralis
ALS: 14
HCs: 10
Myo-miRNAs and miRNAs
dysregulated in human
muscle disease→ qRT-PCR
[91]
1, 26a, 133a, 455 ↓ Vastus lateralis ALS: 5HCs: 7 Myo-miRNAs→ qRT-PCR [92]
424, 214, 206 ↑ Biceps brachii ALS: 5HCs: 5
Microarray→miRNAs
validation with qRT-PCR [72]
1, 206, 133a,
133b, 27a, 155,
146a, 221
↑ Quadriceps
femoris
SALS: 13
HCs: 5
Inflammatory/angiogenic
miRNAs and myo-miRNAs
→ qRT-PCR
[93]
1, 10b-5p,
100-5p, 133a-3p,
133b-3p
↓
Biceps, deltoid,
tibialis anterior,
vastus lateralis
ALS: 19
HCs: 9
NGS 1 and qRT-PCR 1 →
qRT-PCR
[94]
100-5p, 10a,
125a-5p,
133a-1/-2-3p,
362, 500a-3p,
542-5p, 99a-5p
1303-3p, 150-5p,
26a-1/-2-5p,
486-1/-2-5p,
↑
↓
Vastus lateralis
FALS: 2
SALS: 9
HCs: 11
NGS [95]
1 analysis carried out on samples from transgenic mice. Abbreviations: Ref., Reference; ↑/↓,
up-regulated/down-regulated; SALS, sporadic amyotrophic lateral sclerosis patients; FALS, familial amyotrophic
lateral sclerosis patients; HCs, healthy controls; qRT-PCR, quantitative Real-Time Polymerase Chain Reaction;
NGS, Next Generation Sequencing.
Some authors performed also a correlation analysis among miRNA expression and ALS clinical
features. Table 5 reports miRNAs altered in tissue of specific stratified ALS patients’ groups analyzed
in comparison to control subjects.
In addition, in other papers the associations with clinical variables were analyzed comparing
groups of patients to each other. Stratifying ALS patients, an up-regulation of myo-miRNAs (miR -206,
miR-133a, miR-133b and miR-27a) and of inflammatory miRNAs (miR-155, miR-146a and miR -221)
was discovered in ALS patients with earlier age at onset (<55 years) and longer disease duration [93].
Moreover, significantly higher expression levels of the same myo-miRNAs and inflammatory miRNAs
were detected in male than in female. This gender difference has been hypothesized to be related to a
difference in hormonal regulation, implying a slower disease progression in women [93]. In another
paper, miR-29c, miR-208b and miR-499 were reported as increased in patients with slow disease
course [96]. Expression data were analyzed in patients categorized into “early” and “late” based on
disease duration at the moment of biopsy (more or less one year). miR-9 and miR-206 significantly
increased in the early patients’ group and, of note, miR-206 inversely correlated with the time from
symptoms onset to muscle biopsy, indicating an early response to denervation in skeletal muscle [96].
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Table 5. Deregulated miRNAs in skeletal muscle biopsies of specific amyotrophic lateral sclerosis (ALS)
patients’ groups analyzed in comparison to healthy controls.
miRNA
(Hsa-miR)
miRNA Expression
Change in Specific
ALS Patients’ Group
Type of
Muscle
No. of Muscle
Biopsies
miRNA
Detection
Approach
Ref.
133a, 29c, 9,
208b
1, 208b
133a, 133b, 206,
29c, 9, 155, 23a
↑in ALS slow group 1
↓ in ALS rapid group 2
↑ in early stage group 3
Deltoid and
quadriceps
FALS: 3
SALS: 11
HCs: 24
Slow group 1: 6
Rapid group 2: 5
Early group 3: 4
Late group 4:9
Eleven skeletal
muscle related
miRNAs→
qRT-PCR
[96]
100-5p,
199a-1/-2,
199b-3p, 27a-5p,
3607-3p, 424-5p,
450a-1/-2-5p,
450b-5p,
501-3p,
502-3p, 542-5p,
660-5p
1303-3p,
133a-1/-2-3p,
150-5p, 378,
486-1/-2-5p,
502-3p, 855-3p
↑ in higher disease
severity 5
↓ in higher disease
severity 5
Vastus
lateralis
Higher disease
group 5: 7
HCs: 11
NGS [95]
1, ALS slow group (≥4 years of disease progression without requiring respiratory supports); 2, ALS rapid group
(<4 years of disease progression without respiratory supports or death occurring <4 years from symptoms onset);
3, early stage group (less than one year from symptom onset to muscle biopsy); 4, late stage group (more than
one year from symptom onset to muscle biopsy); 5, group of patients with higher disease severity. Abbreviations:
Ref., Reference; ↑/↓, up-regulated/down-regulated; SALS, sporadic amyotrophic lateral sclerosis patients; FALS,
familial amyotrophic lateral sclerosis patients; HCs, healthy controls; qRT-PCR, quantitative Real-Time Polymerase
Chain Reaction; NGS, Next Generation Sequencing.
Although the results are often inconsistent among different studies, some trends in miRNAs
deregulation seem to emerge. One of the most interesting miRNA is miR-133a, which was found to be
up-regulated in human ALS tissues [93,95,96], particularly in patients with slow disease progression
and in biopsies obtained before one year from the symptom onset [96]. At the same time, a significant
reduction of this miRNA was present in a specific ALS patients’ group with higher disease severity [95],
suggesting changes in its expression during the disease progression. In contrast, however, other studies
detected a down-regulation of miR-133a in human biopsies, as reported also in mice [92,94]. At the
moment, the strongest data are those concerning miR-206. Indeed, the mechanisms responsible for
the increase of this miRNA seem to be conserved in the skeletal muscle of mouse models and in that
from ALS patients, and the up-regulation described in both cases is an ALS-specific response to the
denervation. miR-206 was found significantly up-regulated in muscle samples from ALS patients
compared to control subjects [72,90,91,93], similarly to what observed in blood samples, strengthening
the role of this miRNA as potential biomarker for ALS. Of note, miR-206 showed an increased trend in
muscle biopsies from long-term survivor patients, even though below the statistically significance [90].
De Andrade and colleagues [72] reported that this miRNA was over-expressed both in plasma and
skeletal muscle of patients with ALS, but the over-expression was not progressive during the follow-up.
They supposed that miR-206 expression increased early in the disease course, reaches a plateau and
then begins to fall. In agreement with this hypothesis, an up-regulation of miR-206 was described
in muscle biopsies from ALS patients within one year from the clinical onset, becoming less evident
as the disease progresses to a later stage [96]. Finally, Si and collaborators reported a non-significant
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upward trend in miR-206 in muscle samples from ALS patients compared to controls. This result,
however, was correlated to a high standard error for this miRNA due to the variability among samples.
Moreover, the authors reported a significant inverse correlation between this miRNA and the muscle
power of the biopsied muscle, hypothesizing that it could be a marker of disease activity. This finding
highlights the importance to associate miR-206 levels with muscle-specific clinical assessment rather
than overall clinical status [94].
Although a concordant miRNA signature have not been identified yet in ALS patient muscle
biopsies, these findings show that miRNAs could be useful prognostic markers to better understand
the course of disease. In particular, the identification of a specific muscular miRNA profile through
multicenter studies, able to increase the statistical power of the analysis, could lead to a stratification
of the patients in order to identify prognostic biomarkers to use as indicator of disease progression,
facilitating the clinical management of patients.
5. Conclusions and Future Perspectives
Despite the intense research activity of the last years, the use of miRNAs as biomarkers for
diagnosis of ALS and clinical management of patients is still in an early stage of development.
Several interesting data have been obtained so far, with important insights into the disease processes.
However, results achieved in different studies are most of the time conflicting and poorly reproducible,
making it difficult to unequivocally identify which miRNA(s) may be selected as biomarker in clinical
practice. In order to overcome these limits, some improvements in the research approach should be
taken into account.
First of all, one factor strongly complicating the comparison among data reported by different
research groups is the wide range of methods used for the identification of potential miRNA biomarkers
and the different techniques for miRNA measurement and data normalization. A common acceptance
of certain guidelines, standard research protocols, and strong methods of statistical analysis of miRNAs
will be important in the future to achieve reliable biomarkers.
Another critical issue is the relatively small number of patients included in the studies performed
until now. Results are often interesting, but they need to be verified in larger cohorts of ALS patients.
It would be really important that those miRNAs, which have shown initial promise, were validated
in independent laboratories and/or in multicenter collaborations. In addition, since ALS is a highly
heterogeneous disease, replication studies should increase the number of patients stratifying them
based on clinical and genetic features, in order to obtain a better assessment of the potential associations
among miRNAs and these variables.
Further, in several studies miRNA levels of ALS patients have been compared only to those of
control subjects not affected by neurological disorders. This approach may bring to the identification
of miRNAs able to successfully differentiate patients from healthy control subjects, but these miRNAs
are often associated with common pathologic processes of neurodegeneration and are not specific
for ALS. It will be of fundamental importance to extend the comparison to patients affected by
other neurodegenerative diseases, in particular ALS-mimic disorders, to evaluate the specificity of
deregulated miRNAs for ALS.
One of the more interesting approaches to miRNA biomarker identification is the use of a complex
set of biomarkers, or combinations or ratios of biomarkers from different pathogenic pathways,
rather than the employ of a single marker. This strategy has been shown to increase the sensitivity
and/or specificity of potential ALS biomarkers and to contain more exhaustive diagnostic information,
and should be more widely used in future researches.
At the same time, when possible, future studies should try to combine data obtained from
multiple source of sample (blood, CSF, muscle) of the same patient. Up to date, only few studies
have performed this kind of analysis, and their results are quite conflicting. However, an extensive
analysis of correlations among different samples could be helpful to obtain more informative data and
improve patients’ stratification. In addition, for circulating miRNAs, it would be important to perform
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longitudinal studies on a large number of patients, in order to identify potential biomarkers of disease
progression, and evaluate their role as prognostic indicators.
In conclusion, miRNAs constitute very promising biomarkers for ALS, but there is still much
work to be done to validate and use them in clinical routine. The ultimate objective is to include
these biomarkers in all phases of ALS management, from the diagnosis to the clinical trials, and,
in perspective, to the identification of future therapeutic approaches.
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